Tyrosine-kinase inhibitors are recent therapy used in different neoplastic diseases. Dysthyroidism seems to be a class effect of these drugs with a potentially cross cumulative effect. We describe here the case of a man who first developed dysthyroidism with sunitinib, then a deep and permanent hypothyroidism when axitinib was introduced.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2515/therapie/2014063 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Not Available].
Therapie
July 2016
Centre régional de pharmacovigilance, CHU de Grenoble, Grenoble, France.
Tyrosine-kinase inhibitors are recent therapy used in different neoplastic diseases. Dysthyroidism seems to be a class effect of these drugs with a potentially cross cumulative effect. We describe here the case of a man who first developed dysthyroidism with sunitinib, then a deep and permanent hypothyroidism when axitinib was introduced.
View Article and Find Full Text PDF[Dysthyroidism with anti-VEGF treatment, a class effect? about one case report].
Therapie
February 2015
Centre régional de pharmacovigilance, CHU de Grenoble, Grenoble, France.
Tyrosine-kinase inhibitors are recent therapy used in different neoplastic diseases. Dysthyroidism seems to be a class effect of these drugs with a potentially cross cumulative effect. We describe here the case of a man who first developed dysthyroidism with sunitinib, then a deep and permanent hypothyroidism when axitinib was introduced.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!